BEDFORD, Mass.– Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer. In this role, Mr. Leggett will be responsible for overseeing all aspects of the Company’s financial strategy and operations. Mr. Leggett succeeds Stephen Tulipano, CPA, MBA, who resigned his position as Stoke’s Chief Financial Officer effective Tuesday, May 7.
“I want to thank Mr. Tulipano for his contributions to Stoke over the past five years. He has led multiple financings, including Stoke’s highly successful Initial Public Offering in 2019 and the recent $125M public offering and leaves the Company well positioned to execute on our goal of delivering the first potential disease-modifying therapy to patients with Dravet syndrome,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “We welcome Mr. Leggett to Stoke and look forward to working with him to build on this strong foundation as Stoke enters a new phase of growth, starting with advancing STK-001 into a registrational study and looking ahead to developing our pipeline of potential disease-modifying medicines.”
“The recently announced landmark data from the studies of STK-001 for the treatment of Dravet syndrome mark the start of a very exciting time for Stoke as it transitions to a late-stage clinical company while building a commercial organization,” said Mr. Leggett. “I look forward to working with the Stoke leadership team and share their deep commitment to Stoke’s mission of delivering novel new medicines to people living with severe diseases like Dravet syndrome.”
Mr. Leggett brings more than 20 years of experience as a biotechnology executive, board member and as an investment banker. He has led financial strategy and operations and secured financing for dozens of life science companies. Prior to joining Stoke, Mr. Leggett served as Chief Financial Officer at Affinia Therapeutics. Before joining Affinia Therapeutics, Mr. Leggett was Chief Financial Officer at Black Diamond Therapeutics, where he led the Company’s $85 million Series C financing and $231 million IPO. Before joining Black Diamond, Mr. Leggett served as Chief Financial Officer at Axcella Health, where he helped raise $156 million across three financings, including an IPO. Mr. Leggett spent more than a decade as an investment banker for the healthcare groups at J.P. Morgan Securities, Lazard Frères & Company, and UBS Securities. Mr. Leggett also currently serves on the board of directors of Clover Biopharmaceuticals, Ltd.
Mr. Leggett holds a Master of Business Administration in Finance from the Wharton School at the University of Pennsylvania and earned his Bachelor of Arts in Economics from Columbia University.
